Editorial Commentary
Strengthening the EGFR blockade for those lung cancers that need it most
Translational Lung Cancer Research
2026;
15
(7)
:191
.
(31 July 2026)
The detection of MTAP loss in non-small cell lung cancer: a novel biomarker with therapeutic implications
Translational Lung Cancer Research
2026;
15
(7)
:192
.
(31 July 2026)
Trophoblast cell-surface antigen 2-targeted “sacituzumab tirumotecan”: a new approach for epidermal growth factor receptor-tyrosine kinase inhibitor-resistant non-small cell lung cancer
Translational Lung Cancer Research
2026;
15
(7)
:193
.
(31 July 2026)
Original Article
CT-derived abdominal organ volumetrics for predicting recurrence-free and disease-free survival in resected non-small cell lung cancer: a multicenter retrospective cohort study
Translational Lung Cancer Research
2026;
15
(7)
:194
.
(31 July 2026)
Real-world analysis in patients with limited-stage small-cell lung cancer who received durvalumab after concurrent chemoradiotherapy
Translational Lung Cancer Research
2026;
15
(7)
:195
.
(31 July 2026)
Multiplexed quantitative proteomics in small-cell lung cancer: stage-linked DLL3 distribution and an independent prognostic signal of thymidine phosphorylase
Translational Lung Cancer Research
2026;
15
(7)
:196
.
(31 July 2026)
Tertiary lymphoid structures predict the neoadjuvant chemoimmunotherapy response of stage III non-small cell lung cancer
Translational Lung Cancer Research
2026;
15
(7)
:197
.
(31 July 2026)
Promising benefits of MET inhibition combined with EGFR/ALK tyrosine kinase inhibitor in heavily treated non-small cell lung cancer patients with EGFR-mutant/ALK rearrangement and MET overexpression: a retrospective cohort study
Translational Lung Cancer Research
2026;
15
(7)
:198
.
(31 July 2026)
Development and validation of a machine learning model for predicting objective response to PD-1 inhibitors in lung cancer patients
Translational Lung Cancer Research
2026;
15
(7)
:199
.
(31 July 2026)
Intratumor immune heterogeneity across simulated core biopsy sizes in non-small cell lung cancer: an exploratory study
Translational Lung Cancer Research
2026;
15
(7)
:200
.
(31 July 2026)
Elevated serum neuron-specific enolase as an indicator of poor chemo-immunotherapy outcomes and reduced CD8-positive lymphocyte infiltration in small-cell lung cancer: a retrospective cohort study
Translational Lung Cancer Research
2026;
15
(7)
:201
.
(31 July 2026)
FOXA1 drives chemoresistance through activating Wnt pathway in small cell lung cancer
Translational Lung Cancer Research
2026;
15
(7)
:202
.
(31 July 2026)
Longevity-associated FOXO3 genotype mitigates the risk of lung cancer after smoking cessation: a prospective cohort study
Translational Lung Cancer Research
2026;
15
(7)
:203
.
(31 July 2026)
Non-destructive three-dimensional structural assessment of transbronchial cryobiopsy specimens using phase-contrast X-ray CT: a proof-of-concept study
Translational Lung Cancer Research
2026;
15
(7)
:204
.
(31 July 2026)
A retrospective cohort study integrating invasive mucinous adenocarcinoma into the IASLC grading system for lung adenocarcinoma
Translational Lung Cancer Research
2026;
15
(7)
:205
.
(31 July 2026)
Baseline IL-6, IL-8, IFN-ω, and perforin as prognostic biomarkers in immune checkpoint inhibitor-treated metastatic non-small cell lung cancer
Translational Lung Cancer Research
2026;
15
(7)
:206
.
(31 July 2026)
Treatment patterns and outcomes of later-line therapy in advanced non-small cell lung cancer with unknown or no actionable genomic alterations: a multicenter real-world study in China (RECAP study)
Translational Lung Cancer Research
2026;
15
(7)
:207
.
(31 July 2026)
Best supportive care in stage I–III non-small cell lung cancer: survival by reason for curative treatment omission in a real-world study population
Translational Lung Cancer Research
2026;
15
(7)
:208
.
(31 July 2026)
Development and validation of machine learning diagnostic models integrating clinical, CT, and laboratory features to differentiate lung cancer from pulmonary tuberculosis in patients with solitary pulmonary nodules: a single-center retrospective study
Translational Lung Cancer Research
2026;
15
(7)
:209
.
(31 July 2026)
Predictors of prolonged hospital stay in patients with lung cancer undergoing sublobar resection
Translational Lung Cancer Research
2026;
15
(7)
:210
.
(31 July 2026)
Association of symptoms at diagnosis with prognosis in patients with surgically treated stage I non-small cell lung cancer: a retrospective cohort analysis of a prospectively maintained registry
Translational Lung Cancer Research
2026;
15
(7)
:211
.
(31 July 2026)
Study Protocol
Neoadjuvant befotertinib plus vorolanib in resectable stage II–IIIB EGFR-mutant NSCLC: a study protocol for the prospective, single-arm phase I/II trial
Translational Lung Cancer Research
2026;
15
(7)
:212
.
(31 July 2026)
Review Article
Epigenetics in lung cancer precision medicine: from bench to bedside—a narrative review
Translational Lung Cancer Research
2026;
15
(7)
:213
.
(31 July 2026)
Deciphering lung cancer at high resolution: a narrative review of applications of single-cell and spatial transcriptomics sequencing
Translational Lung Cancer Research
2026;
15
(7)
:214
.
(31 July 2026)
Immune-preserving radiotherapy and perioperative immunotherapy in stage III NSCLC: a narrative review of current management and future directions for IIIA/IIIB NSCLC
Translational Lung Cancer Research
2026;
15
(7)
:215
.
(31 July 2026)
Role and clinical significance of VISTA (PD-1H) and PVR (CD155) expression in non-small cell lung carcinoma: a systematic review
Translational Lung Cancer Research
2026;
15
(7)
:216
.
(31 July 2026)
Targeted therapeutic strategies for KRAS-G12D-mutant non-small cell lung cancer: a narrative review
Translational Lung Cancer Research
2026;
15
(7)
:217
.
(31 July 2026)
